久久亚洲国产成人影院-久久亚洲国产的中文-久久亚洲国产高清-久久亚洲国产精品-亚洲图片偷拍自拍-亚洲图色视频

Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / Industries

Investors jump on healthcare bandwagon

By LIU ZHIHUA | China Daily | Updated: 2020-12-23 11:01
Share
Share - WeChat
Researchers from the Innovative Institute of Nanjing Oncoly Biomedical T-chnology conduct a biopharmaceutical experiment in April. [Photo provided to China Daily]

Research and development, commercialization of vaccines and antiviral drugs to boost spending on innovative projects

China's healthcare investment is booming as COVID-19 has led to a surge of interest in related sectors.

Hongtai Aplus, with two funds worth some 5 billion yuan ($765 million) targeting the healthcare sector, has already finalized three medical projects so far this year, with several others now undergoing due diligence.

Founded in 2014 by renowned entrepreneur Yu Minhong and veteran banker Sheng Xitai, the firm invested in three medical projects-two involving innovative drugs and one in testing procedures-from 2018 to 2019.

According to global consultancy McKinsey & Co, there has been a strong rebound of healthcare venture capital/private equity investment in 2020 after a decline in 2019.The total amount of VC/PE investment in the sector during the first half had already exceeded that for the whole of 2019.

"COVID-19 has had a profound influence on the economy and significantly propelled investment into China's healthcare sector," said Jiang Fei, managing director of Hongtai Aplus.

Due to the outbreak of COVID-19, need for protection and treatment has surged, benefiting medical devices and testing companies over the short term. And over the long term, research and development and commercialization of vaccines and antiviral drugs will also prompt spending on innovative drug projects, Jiang said.

More than 200 new drug projects have received investment so far this year, up one-third from 2019, among which are large-scale financing projects (including initial public offerings), with single-round financing in excess of 1 billion yuan being three times that were seen last year, Jiang added.

Li Gang, partner of private investment bank CEC Capital, said: "The pandemic has spurred interest in the healthcare industry among the public. This has led to increased supportive government policy measures and both public and private investments into new drug research, testing and protective gear production."

Projects that CEC Capital has completed so far this year are three times that of last year, with acquisitions and financing totaling 30 billion yuan, Li said.

EdiGene Inc-a Beijing-based startup developing genome editing technologies to accelerate drug discovery and develop novel therapeutics for a broad range of diseases-announced completion of a 450-million-yuan round of Series B financing in October.

The investment was led by 3H Health Investment along with other investors including IDG Capital, Lilly Asia Ventures, Huagai Capital and Green Pine Capital Partners. New investors included Sequoia Capital China, Alwin Capital and Kunlun Capital.

Founded in 2015, EdiGene has established four gene editing based platforms and is advancing its early-stage programs into clinical development for patients with congenital diseases and cancer.

The investment will enable the company to further scale up and transform its pipeline into the clinical stage, thus increasing its global presence, said EdiGene CEO Wei Dong.

Due to social distancing caused by the outbreak of COVID-19, financing activities in healthcare were affected for a short period in early 2020. But as soon as business and production were resumed, financing in the sector saw a strong rebound, Wei said.

While the disease has raised interest in China's healthcare industry, the sector has long been popular among investors eyeing the bulging domestic market due to China's large, aging population and increasing middle-income group, industry insiders said.

Jiang said Hongtai Aplus sees a promising future in the healthcare sector.

The fact that China lags far behind developed countries in biotechnology and medical devices and that China's healthcare industry accounts for a relatively low share of the nation's gross domestic product with a wide range of unmet clinical needs indicates great potential for the healthcare industry and abundant related investment opportunities, Jiang added.

In 2019, healthcare-related expenditure in China equaled about 6.6 percent of GDP, compared with 17.7 percent in the United States in 2018, according to official data from the two countries.

Hongtai Aplus is most interested in biotech and medical devices because of the huge technology gap between China and developed countries. Therefore it is possible to have huge flagship firms dominate the two sectors due to China's huge domestic market, if experience from foreign markets is any guide, Jiang said.

The three investment projects the company has completed this year involve pharmaceutical companies with impressive pipelines of innovative drugs.

One is Shenzhen TargetRx Inc, a biopharmaceutical company founded in 2014 focusing on developing international cutting-edge cancer drugs that block the growth and spread of tumors by interfering with specific molecules. The company currently has several products in the pipeline for lung cancer and leukemia, among other maladies.

The second is Hinova Pharmaceuticals Inc, a high-tech innovative drug development company founded in 2013. The company's prostate cancer drug is undergoing phase-three global clinical trials as a promising candidate for a $10-billion annual market sector globally.

The company has also invested in a Shanghai-based company that owns an original drug candidate for type-2 diabetes. China has 114 million people living with diabetes, accounting for about one-fourth of the global diabetic population, according to the International Diabetes Federation.

Both Li and Wei attributed the popularity of China's health sector among investors to the sector's prospects amid an aging demographic shift and the country's deepening reforms.

CEC Capital's Li said accelerating reforms in China's capital market, including a registration-based system for IPOs and lower financial listing requirements, have provided investors clear exit strategies and thus have injected new momentum into healthcare investment.

As the world's second largest economy, China's biotechnology industry is also rising as domestic companies have expanded into almost all sectors of biomedicine.

The healthcare industry is countercyclical, and the popularity of the sector among investors will continue for at least 10 years in China, with changes in both supply and demand.

China's society is aging and undergoing consumption upgrades amid demand for more quality healthcare products and services. Meanwhile, progress in science and technology will lead to industrial upgrades and enhanced user experiences, he said.

The aging society, growing incidences of certain diseases among youth due to lifestyle changes and the ongoing pandemic have jointly raised people's awareness of health and disease management to new heights, leading to greater demand for related products and services, Wei said.

Progress in science and technology also brings more possibilities for disease care such as genetic and cell therapeutics for diseases that were once considered untreatable, he added.

Regulatory reforms in medical products starting in 2015, regular updates to the national reimbursement drug list and growing ranks of domestic talent have jointly injected new momentum into the healthcare industry, making the sector increasingly popular among investors, which in turn propels development, Wei said.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
主站蜘蛛池模板: 一级aaaaaa毛片免费同男同女 | 国产农村乱子伦精品视频 | 久久中文亚洲国产 | 欧美精品一区视频 | 三级黄色免费网站 | 国产亚洲人成在线影院 | 国产亚洲人成网站在线观看 | 亚洲一区二区三区福利在线 | 2019天天操天天干天天透 | 国产欧美一区二区三区免费 | 国产精品欧美一区二区三区不卡 | 99久久精品视香蕉蕉er热资源 | 久久香蕉精品视频 | 荡公乱妇蒂芙尼中文字幕 | 亚洲精品美女在线观看 | 成人高清在线观看 | 欧做爰xxxⅹ性欧美大 | 在线观看精品国内福利视频 | 一级黄色毛片播放 | 成年女人毛片免费播放人 | 日本免费观看的视频在线 | 日韩欧美在线播放 | 国产成人麻豆tv在线观看 | 免费看欧美日韩一区二区三区 | 99热精品在线免费观看 | 国产一区二区免费不卡在线播放 | 久久久久久网站 | caoporen免费公开视频上传 | 国产高清在线免费视频 | 国产在线视频专区 | 欧美一区二区三区免费看 | 亚洲成人偷拍自拍 | 国产成人久久久精品毛片 | 毛片网站免费在线观看 | 国产91综合 | 波多野结衣在线观看一区二区三区 | 欧美片能看的一级毛片 | 欧美另类丝袜 | 国产免费黄视频 | 美国三级在线观看 | 国产成人小视频在线观看 |